An interspecies extrapolation of the pharmacokinetics of telavancin, a rapidly bactericidal, concentration-dependent antibiotic

References

• Bhamidipati RK, Dravid PV, Mullangi R, Srinivas NR. (2004). Prediction of clinical pharmacokinetic parameters of linezolid using animal data by allometric scaling: applicability for the development of novel oxazolidinones. Xenobiotica 34:571–579.
   PubMed Web of Science ®Google Scholar
• Cox SK. (2007). Allometric scaling of marbofloxacin, moxifloxacin, danofloxacin and difloxacin pharmacokinetics: a retrospective analysis. J Vet Pharmacol Ther 30:381–386.
   PubMed Web of Science ®Google Scholar
• Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–1095.
   PubMed Web of Science ®Google Scholar
• Feng MR, Lou X, Brown RR, Hutchaleelaha A. (2000). Allometric pharmacokinetic scaling: towards the prediction of human oral pharmacokinetics. Pharm Res 17:410–418.
   PubMed Web of Science ®Google Scholar
• Hegde SS, Reyes N, Skinner R, Difuntorum S. (2008). Efficacy of telavancin in a murine model of pneumonia induced by methicillin-susceptible Staphylococcus aureus. J Antimicrob Chemother 61:169–172.
   PubMed Web of Science ®Google Scholar
• Hegde SS, Reyes N, Wiens T, Vanasse N, Skinner R, McCullough J, Kaniga K, Pace J, Thomas R, Shaw JP, Obedencio G, Judice JK. (2004). Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria. Antimicrob Agents Chemother 48:3043–3050.
   PubMed Web of Science ®Google Scholar
• Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. (2006). High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 166:2138–2144.
   PubMed Web of Science ®Google Scholar
• Higgins DL, Chang R, Debabov DV, Leung J, Wu T, Krause KM, Sandvik E, Hubbard JM, Kaniga K, Schmidt DE Jr, Gao Q, Cass RT, Karr DE, Benton BM, Humphrey PP. (2005). Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 49:1127–1134.
   PubMed Web of Science ®Google Scholar
• Krause KM, Renelli M, Difuntorum S, Wu TX, Debabov DV, Benton BM. (2008). In vitro activity of telavancin against resistant gram-positive bacteria. Antimicrob Agents Chemother 52:2647–2652.
   PubMed Web of Science ®Google Scholar
• Leonard SN, Rybak MJ. (2008). Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious gram-positive infections. Pharmacotherapy 28:458–468.
   PubMed Web of Science ®Google Scholar
• Madrigal AG, Basuino L, Chambers HF. (2005). Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 49:3163–3165.
   PubMed Web of Science ®Google Scholar
• Mahmood I. (2007). Application of allometric principles for the prediction of pharmacokinetics in human and veterinary drug development. Adv Drug Deliv Rev 59:1177–1192.
   PubMed Web of Science ®Google Scholar
• Mahmood I, Balian JD. (1996). Interspecies scaling: predicting clearance of drugs in humans. Three different approaches. Xenobiotica 26:887–895.
   PubMed Web of Science ®Google Scholar
• Mahmood I, Balian JD. (1996). Interspecies scaling: predicting pharmacokinetic parameters of antiepileptic drugs in humans from animals with special emphasis on clearance. J Pharm Sci 85:411–414.
   PubMed Web of Science ®Google Scholar
• Miró JM, García-de-la-Mària C, Armero Y, de-Lazzari E, Soy D, Moreno A, del Rio A, Almela M, Mestres CA, Gatell JM, Jiménez-de-Anta MT, Marco F; Hospital Clínic Experimental Endocarditis Study Group. (2007). Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 51:2373–2377.
   PubMed Web of Science ®Google Scholar
• Moise-Broder PA, Sakoulas G, Eliopoulos GM, Schentag JJ, Forrest A, Moellering RC Jr. (2004). Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis 38:1700–1705.
   PubMed Web of Science ®Google Scholar
• Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ, Wastall P. (1997). The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283:46–58.
   PubMed Web of Science ®Google Scholar
• Reyes N, Skinner R, Benton BM, Krause KM, Shelton J, Obedencio GP, Hegde SS. (2006). Efficacy of telavancin in a murine model of bacteraemia induced by methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 58:462–465.
   PubMed Web of Science ®Google Scholar
• Reyes N, Skinner R, Kaniga K, Krause KM, Shelton J, Obedencio GP, Gough A, Conner M, Hegde SS. (2005). Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 49:4344–4346.
   PubMed Web of Science ®Google Scholar
• Rubinstein E, Corey GR, Stryjewski ME, Boucher HW, Daly RN, Genter FC, Barriere SL, Kitt MM, Friedland HD. (2008). Telavancin for hospital-acquired pneumonia, including ventilator-associated pneumonia: the ATTAIN studies. 18th European Congress of Clinical Microbiology and Infectious Diseases; April 19-22, 2008; Barcelona, Spain.
   Google Scholar
• Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM. (2004). Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 42:2398–2402.
   PubMed Web of Science ®Google Scholar
• Shaw JP, Adams SM, Li DN, Seroogy J, Jaw-Tsai S. (2002). Preclinical pharmacokinetics and allometric scaling of vancomycin. AAPS J 4:689 (Abstract).
   Google Scholar
• Shaw JP, Seroogy J, Kaniga K, Higgins DL, Kitt M, Barriere S. (2005). Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob Agents Chemother 49:195–201.
   PubMed Web of Science ®Google Scholar
• Sinha VK, De Buck SS, Fenu LA, Smit JW, Nijsen M, Gilissen RA, Van Peer A, Lavrijsen K, Mackie CE. (2008). Predicting oral clearance in humans: how close can we get with allometry? Clin Pharmacokinet 47:35–45.
   PubMed Web of Science ®Google Scholar
• Stryjewski ME, Graham DR, Wilson SE, O’Riordan W, Young D, Lentnek A, Ross DP, Fowler VG, Hopkins A, Friedland HD, Barriere SL, Kitt MM, Corey GR; Assessment of Telavancin in Complicated Skin and Skin-Structure Infections Study. (2008). Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis 46:1683–1693.
   PubMed Web of Science ®Google Scholar
• Stucki A, Gerber P, Acosta F, Cottagnoud M, Cottagnoud P. (2006). Efficacy of telavancin against penicillin-resistant pneumococci and Staphylococcus aureus in a rabbit meningitis model and determination of kinetic parameters. Antimicrob Agents Chemother 50:770–773.
   PubMed Web of Science ®Google Scholar
• Theravance, Inc. (2008). Data on file. VIBATIV package insert available at: http://www.vibativ.com/PrescribingInformation.aspx.
   Google Scholar
• Wang G, Hindler JF, Ward KW, Bruckner DA. (2006). Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol 44:3883–3886.
   PubMed Web of Science ®Google Scholar
• Wong SL, Barriere SL, Kitt MM, Goldberg MR. (2008). Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects. J Antimicrob Chemother 62:780–783.
   PubMed Web of Science ®Google Scholar
• World Health Organization. (2000). Overcoming antimicrobial resistance. World health report on infectious diseases 2000. A message from the Director-General, World Health Organization. Available at: http://www.who.int/infectious-disease-report/2000/other_versions/index-rpt2000_text.html. Accessed on May 8, 2008.
   Google Scholar